招银国际:首次覆盖维立志博-B(09887.HK)予“买入”评级 目标价63.5港元

智通财经
Sep 04
【招银国际:首次覆盖维立志博-B(09887.HK)予“买入”评级 目标价63.5港元】智通财经APP获悉,招银国际发布研报称,维立志博-B(09887.HK)专注于开发涉及免疫检查点的免疫疗法,例如共刺激激动剂和检查点抑制剂,同时拓展至其他领域,例如CD3 T细胞衔接剂和抗体偶联药物(ADC)。公司已开发出专有的Leads Body平台和X-body平台,该等平台是持续药物发现的引擎。该行对维立志博开发PD-L1/4-1BB和TCE作为下一代IO持乐观态度,首次覆盖予“买入”评级,目标价63.5港元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10